Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Kielezo cha SCORAD (Kupima Ukali wa Ugonjwa wa Ngozi unaosababishwa na Mzio)× | Skindex-29 (Kipimo cha Ubora wa Maisha wa Magonjwa ya Ngozi)× | |
|---|---|---|
| Nyanja | Dermatolojia | Dermatolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1993 | 1997 |
| Mwanzilishi≠ | European Task Force on Atopic Dermatitis (ETFAD) | Chren MM, Lasek RJ |
| Aina≠ | Clinician-rated | Self-report |
| Chanzo asilia≠ | Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19. DOI ↗ | Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713. DOI ↗ |
| Majina mbadala≠ | SCORAD Index | Skindex, Skindex-QoL |
| Zinazohusiana≠ | 3 | 1 |
| Muhtasari≠ | The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice. | Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes. |
| ScholarGateSeti ya data ↗ |
|
|